The Life Sciences team advised Relay Therapeutics, Inc. (Nasdaq: RLAY) on its acquisition of ZebiAI.

Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational, and experimental technologies.

ZebiAI is a pioneer in applying massive experimental DNA encoded library data sets to power machine learning for drug discovery (ML-DEL).

Together, Relay Therapeutics and ZebiAI aspire to accelerate the application of machine learning across the Dynamo™ platform to potentially fast-track the finding of novel medicines against intractable targets.

Under the terms of the merger agreement, Relay Therapeutics will pay $85 million upfront, comprised of $20 million in cash and $65 million in Relay Therapeutics common stock. ZebiAI stockholders are also eligible to receive up to an additional $85 million in platform and program-related milestone payments, payable in Relay Therapeutics common stock. Additionally, if Relay Therapeutics enters partnering or collaboration agreements related to ZebiAI’s platform, ZebiAI stockholders are eligible to receive 10% of the payments received within the next three years, up to an aggregate cap of $100 million payable in cash.

The Goodwin team consisted of Mitch Bloom, Bill Collins, Ed Amer, Nicole Fontes, and Taylor Harrison (M&A); Kathleen Kean, Yasee Zahedi, and Tina Zakhary (Licensing and Intellectual Property); Dan Karelitz and Nicole Spiteri (Tax); Gaby Morales-Rivera and Jason Goldfarb (Corporate); Sarah BockBrad Smith and with invaluable assistance from Robert Frederickson, Courtney Hetrick and Caroline Galiatsos.

For more details, read the press release and articles in Endpoints, BioSpace, and Boston Business Journal.